{"filing":{"accession_number":"0001193125-26-276738","cik":"0001806310","ticker":"TSHA","company_name":"Taysha Gene Therapies, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d20817d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817d8k.htm"},"events":[{"id":12621,"run_id":11194,"accession_number":"0001193125-26-276738","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Taysha announced completion of dosing in the REVEAL pivotal trial for TSHA-102 and reported positive longer-term clinical data from Part A, including 100% of patients gaining/regaining developmental milestones and 310 total functional gains at ≥12 months post-treatment, representing a material clinical and regulatory milestone advancing toward BLA submission in 1H 2027.","company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9525,"accession_number":"0001193125-26-276738","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Taysha announced completion of dosing in the REVEAL pivotal trial for TSHA-102 and reported positive longer-term clinical data from Part A, including 100% of patients gaining/regaining developmental milestones and 310 total functional gains at ≥12 months post-treatment. This is a material clinical and regulatory milestone for a lead gene therapy program advancing toward BLA submission in 1H 2027, representing significant operational progress in drug development rather than a financial event, M\u0026A activity, or governance matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:15:11.519425+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9526,"accession_number":"0001193125-26-276738","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses completion of dosing in the REVEAL pivotal trial for TSHA-102 and positive longer-term clinical data from Part A of the REVEAL Phase 1/2 trials for Rett syndrome treatment. This represents a material clinical and regulatory milestone—100% of patients gained/regained developmental milestones with durable treatment effects and no serious adverse events—that advances the company toward a potential BLA submission expected in 1H 2027. While this is clinical-stage progress rather than a traditional earnings release or regulatory approval, it is a significant operational and strategic milestone that would materially affect investor assessment of the company's pipeline advancement and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:15:11.519425+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9525,"accession_number":"0001193125-26-276738","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Taysha announced completion of dosing in the REVEAL pivotal trial for TSHA-102 and reported positive longer-term clinical data from Part A, including 100% of patients gaining/regaining developmental milestones and 310 total functional gains at ≥12 months post-treatment. This is a material clinical and regulatory milestone for a lead gene therapy program advancing toward BLA submission in 1H 2027, representing significant operational progress in drug development rather than a financial event, M\u0026A activity, or governance matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:15:11.519425+00:00","company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","filing_date":"2026-06-22"},{"id":9526,"accession_number":"0001193125-26-276738","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses completion of dosing in the REVEAL pivotal trial for TSHA-102 and positive longer-term clinical data from Part A of the REVEAL Phase 1/2 trials for Rett syndrome treatment. This represents a material clinical and regulatory milestone—100% of patients gained/regained developmental milestones with durable treatment effects and no serious adverse events—that advances the company toward a potential BLA submission expected in 1H 2027. While this is clinical-stage progress rather than a traditional earnings release or regulatory approval, it is a significant operational and strategic milestone that would materially affect investor assessment of the company's pipeline advancement and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:15:11.519425+00:00","company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","filing_date":"2026-06-22"}]}